Pharmacovigilance (PV) compliance is more than a regulatory checkbox – it’s a commitment to patient safety. For small and mid-sized pharma companies, staying compliant while scaling can feel overwhelming. Expensive, complex PV systems designed for Big Pharma don’t always fit the needs, or the budgets, of emerging biopharma teams. Our recent blog post, breaks down the topic and potential solutions to these challenges.

Pharmacovigilance activities are necessary to ensure the detection, assessment, understanding and prevention of adverse effects.

Health Canada has updated GUI-0119 to help companies comply with GMP for fabricating and packaging/labelling of sterile drugs.